SCHEMBL25754717

SCHEMBL25754717

CC#CC(=O)CNCCOCCCN1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 10/20 0.40
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
CHRM2 P08172 1/20 0.36
ADRA2C P18825 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
HRH1 P35367 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KCNH2 Q12809 1/20 0.36
CACNA1C Q13936 1/20 0.36
SCN5A Q14524 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MAOB P27338 1/20 0.36
CYP1A2 P05177 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754731 0.92 KDM4E (0.39) HRH3POLBMAPTKDM4ECYP1A2
SCHEMBL25754758 0.89 HRH3 (0.39) HRH3POLBMAPTCHRM2ADRA2C
SCHEMBL25754697 0.85 RAD52 (0.40) HRH3MAPTSCN5AKDM4ECYP1A2
SCHEMBL25754752 0.81 SMN1; SMN2 (0.38) HRH3POLBMAPTCHRM2ADRA2C
SCHEMBL25754615 0.80 HRH3 (0.42) HRH3POLBMAPTCHRM2ADRA2C
SCHEMBL25754610 0.80 HRH3 (0.42) HRH3POLBMAPTCHRM2ADRA2C
SCHEMBL25754712 0.79 KMT2A (0.38) POLBMAPTKDM4E
SCHEMBL25754594 0.79 CYP1A2 (0.42) HRH3POLBMAPTCHRM2ADRA2C
SCHEMBL25754613 0.77 HRH3 (0.42) HRH3MAPTMAOBCYP1A2MAPK1
SCHEMBL25754339 0.76 EPHX2 (0.34) KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 HRH3 1596/4885POLB 4028/4885MAPT 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.